Company Overview of Plexxikon, Inc.
Plexxikon, Inc. is engaged in the discovery and development of small molecule pharmaceuticals to treat human diseases. The company’s pipeline comprises Zelboraf (vemurafenib), an oral, small molecule, and kinase inhibitor that targets the BRAF mutation, occurring in about half of all cases of melanomas; and oral kinase inhibitors for the treatment of cardiovascular and renal diseases, including polycystic kidney disease, hypertension, and atherosclerosis. Its pipeline also includes agents to treat neurological diseases, including pain, multiple sclerosis, and Alzheimer's disease; agents that target to address unmet medical needs in rheumatoid arthritis, as well as other inflammation disorder...
91 Bolivar Drive
Berkeley, CA 94710
Founded in 2000
Key Executives for Plexxikon, Inc.
Co-Founder and Vice President of Commercial and Business Development
Co-Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2013.
Plexxikon, Inc. Key Developments
Plexxikon, Inc. Presents at BioPharm America 2013, Sep-17-2013 05:15 PM
Sep 17 13
Plexxikon, Inc. Presents at BioPharm America 2013, Sep-17-2013 05:15 PM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States. Speakers: Peter Hirth, Founder and Former CEO.
Plexxikon, Inc. Files Investigational New Drug Program Update for PLX7486, Oral Inhibitor Designed to Treat Certain Cancers; Announces Management Changes
May 31 13
Plexxikon, Inc. announced the promotions of Gideon Bollag, Ph.D., to chief executive officer, Paul Lin, M.D., M.B.A., to chief operating officer, Prabha Ibrahim, Ph.D., to senior vice president of chemistry and nonclinical development, Chao Zhang, Ph.D., to vice president of research and Joseph Young, M.B.A., to treasurer and senior director of finance and corporate development. These management changes follow the retirement from Plexxikon of K. Peter Hirth, Ph.D., Plexxikon's former chief executive officer, and Kathleen Sereda Glaub, M.B.A., former president.
Separately, Plexxikon announced that it has filed an investigational new drug (IND) application for PLX7486, a selective, oral inhibitor that is designed to inhibit proteins believed to promote certain cancers, particularly those involving perineural invasion. Plexxikon recently filed its ninth investigational new drug (IND) application for PLX7486, a selective, oral investigational agent designed to inhibit proteins believed to promote certain cancers, particularly those involving perineural invasion. Tumor cells invade the nerve sheath flanking some cancers, providing an alternative route for metastatic spread and resulting in pain. Perineural invasion is thought to be an indicator of aggressive tumor behavior and has been shown to correlate with poor prognosis. Such invasive cancers also make treatment or surgery much more difficult. Perineural invasion is a prominent characteristic of most pancreatic cancers, and multiple other tumor types. In preclinical models of both cancer and pain, PLX7486 has been shown to have activity in inhibiting tumor growth and reducing pain. A Phase 1 clinical trial is expected to start in the latter half of 2013.
Boundary, Inc. and Plexxikon, Inc. Introduce Real-Time Application-Defined Network
Feb 5 13
Boundary, Inc. and Plexxikon, Inc. entered into a strategic partnership based on a shared vision: to give IT professionals the data and optimally abstracted infrastructure to drive better application performance. As a result of this partnership, IT departments, data center operators and cloud service providers will be better able to optimize networks and support mission-critical application workloads. With Boundary, Plexxi's customers can automate and enhance the configuration of their networks in near real time based on actual application topology and flow analytics. Plexxi builds networks that are designed to help applications perform better dynamically. The more application-specific information available to the network, the more effectively the right resources can be applied in the right places and at the right time. Boundary allows a Plexxi network to automatically get real-time and always-on application topology, throughput and latency data from applications. The successful integration of the Boundary and Plexxi technologies was achieved quickly by leveraging APIs that provide a high-level network abstraction, which enables application performance analytics to drive network optimization without becoming bogged down by network configuration minutia.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|